预约演示
更新于：2026-02-27
Tafluprost
他氟前列素
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 德国 (2008-03-19), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C25H34F2O5 |
InChIKeyWSNODXPBBALQOF-VEJSHDCNSA-N |
CAS号209860-87-7 |
关联
48
项与 他氟前列素 相关的临床试验ChiCTR2500101796
A study of the efficacy and treatment adherence of preservative-free tafluprost based on an electronic patient reporting system
TCTR20210224008
Evaluation of Stability and Sterility of Extended Use of Single-use, Preservative-free 0.0015% Tafluprost Eye Drops: An In Vivo Study.
ChiCTR2100045465
Clinical study on prostaglandin associated periorbitopathy
100 项与 他氟前列素 相关的临床结果
登录后查看更多信息
100 项与 他氟前列素 相关的转化医学
登录后查看更多信息
100 项与 他氟前列素 相关的专利（医药）
登录后查看更多信息
300
项与 他氟前列素 相关的文献（医药）2025-10-08Endocrine Metabolic & Immune Disorders-Drug Targets
Pseudoexfoliation Glaucoma Selective Laser for
Trabeculoplasty Treatment in Vietnam
Article
作者: Nguyen, Kieu CD ; Kim, Thanh Doan ; Isacco, Ciro Gargiulo ; Ke, To Tran ; Palma, Gianna Di ; Santacroce, Luigi ; Cong, Anh Tran ; Minh, Tuan Le
Introduction::
To evaluate the effectiveness of selective laser trabeculoplasty (SLT) in
lowering intraocular pressure (IOP) in Vietnamese patients with pseudoexfoliation glaucoma
(PXG).
Methods::
This prospective, comparative study included a total of 64 eyes from PXG patients who
had not previously received any antiglaucomatous medication. Patients were categorized into two
groups: Group 1 consisted of 32 eyes treated with SLT as the initial therapy, while Group 2 comprised
32 eyes treated with Tafluprost 0.0015%.
Results::
The baseline IOP before treatment ranged from 22 to 26 mmHg. There were no significant
differences between the two groups in terms of mean cup/disc (C/D) ratio and retinal nerve
fiber layer (RNFL) thickness. At the final visit, the mean percentage reduction of IOP was 26.73%
in Group 1 and 27.15% in Group 2.
Discussion::
SLT significantly reduced IOP in PXG patients, with outcomes comparable to
Tafluprost. Treatment was more successful in eyes with higher trabecular pigmentation and early-
stage glaucoma. Structural and functional parameters remained stable over 12 months. Side effects,
including mild itchiness, IOP spikes, and anterior chamber reactions, were transient and manageable.
No vision-threatening complications occurred, confirming SLT as a safe and effective
first-line option for PXG in Vietnamese patients.
Conclusion::
SLT can be effectively used as a primary treatment for PXG. In cases of recurrent
IOP elevation, a second SLT procedure can be administered alone or in combination with other
medications.
2025-08-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation
Article
作者: Sung, Min Kyung ; Kim, Hyun-Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung
Some prostaglandin F2α (PGF2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF2α analogs.
2025-07-07Cureus Journal of Medical Science
Effectiveness and Safety of Switching to Fixed-Dose, Preservative-Free Tafluprost/Timolol in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: A Real-World Study in Taiwan
Article
作者: Lee, Yung-Sung ; Su, Wei-Wen
Objective The objective of this study is to evaluate the effectiveness, safety, and tolerability of a preservative-free fixed-dose combination of tafluprost (0.0015%) and timolol (0.5%) (PF tafluprost/timolol FC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methodology This real-world, prospective, noninterventional study was conducted in Taiwanese patients with OAG or OHT who had an inadequate response or intolerance to topical prostaglandin analogue (PGA) monotherapy and were therefore switched to PF tafluprost/timolol FC. The primary endpoint was the mean change in intraocular pressure (IOP) from baseline to six months after initiating treatment. Changes in clinical signs and subjective symptoms were also evaluated, and adverse events (AEs) were recorded. Results A total of 49 patients were enrolled, and 42 completed the study. The mean ± SD IOP at baseline was 16.5 ± 3.5 mmHg, which significantly decreased to 15.4 ± 3.4 mmHg at six months (absolute reduction: 1.1 ± 2.6 mmHg; p < 0.001). The number of patients with a tear break-up time >10 seconds increased significantly from three (7.5%) at baseline to 22 (52.5%) at six months (p < 0.001). However, a nonsignificant increase was observed in subjective symptoms. Six treatment-related AEs were reported, all of which were nonserious and mild to moderate in severity, including contact dermatitis, redness and itchiness, and blurred vision. Conclusions This real-world, prospective study in Taiwan demonstrated that switching patients with OAG or OHT from PGA monotherapy to PF tafluprost/timolol FC was effective and safe for reducing IOP.
100 项与 他氟前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 开角型青光眼 | 韩国 | 2009-06-26 | |
| 青光眼 | 日本 | 2008-12-16 | |
| 高眼压症 | 芬兰 | 2008-03-19 | |
| 高眼压症 | 德国 | 2008-03-19 | |
| 高眼压症 | 意大利 | 2008-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 虹膜色素剥脱综合征 | 临床3期 | 芬兰 | 2010-12-22 | |
| 角膜疾病 | 临床阶段不明 | 中国台湾 | 2018-04-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | (Group A (treatment-naive or untreated within one month)) | 繭製鏇廠鬱鏇鬱糧淵鹹(觸選選選鏇獵範壓鏇獵) = 廠廠構鹽遞鏇鬱鑰觸鏇 選鬱膚鬱願積壓齋獵築 (製餘範網糧範齋構繭積 ) 更多 | 积极 | 2021-09-05 | ||
Group B (unreached IOP target after previous monotherapy of other PGAs) | 繭製鏇廠鬱鏇鬱糧淵鹹(觸選選選鏇獵範壓鏇獵) = 鏇鏇膚鏇憲衊餘衊糧遞 選鬱膚鬱願積壓齋獵築 (製餘範網糧範齋構繭積 ) 更多 | ||||||
临床4期 | 20 | (Group 1 ("NPT to PT")) | 蓋構醖構簾窪簾繭獵鹹(獵衊廠築繭鏇鹽糧襯構) = TBUT using PT was numerically inferior to that using NPT 願繭獵襯選糧積艱糧夢 (築鹹製窪範壓選蓋顧鹹 ) 更多 | 积极 | 2017-04-28 | ||
(Group 2 ("PT to NPT")) | |||||||
临床4期 | 43 | (Pftafluprost) | 鏇鹹顧襯鹽壓艱築鏇築(範範蓋簾醖願製鏇網醖) = 鹹憲鑰鬱艱鏇廠糧遞構 蓋網衊膚積膚鬱範夢鏇 (遞觸構構餘蓋糧艱艱顧, 3.9) 更多 | 积极 | 2017-01-01 | ||
(triple PF regimen) | 範鹹糧窪衊膚鬱壓鬱齋(壓齋廠築願膚醖築顧簾) = 窪醖顧壓簾醖壓衊鑰糧 齋蓋積淵簾襯齋糧蓋願 (醖夢鹽夢廠廠膚獵艱繭 ) | ||||||
临床3期 | 190 | 淵艱壓積齋鹹築廠蓋構(繭艱鬱夢簾遞糧淵簾衊) = Both PF tafluprost and PF timolol were well-tolerated with similar incidences of adverse events. 鹹糧範衊製襯簾遞簾鏇 (廠築觸醖選壓衊鏇壓齋 ) 更多 | 优效 | 2016-07-01 | |||
临床3期 | 40 | Latanoprost 0.005% + benzalkonium chloride 0.02% | 積齋餘繭膚夢鹽艱膚繭(鹹膚構構鏇蓋齋網顧顧) = 鏇憲願築齋蓋醖窪繭鏇 壓淵選淵鑰艱衊廠衊齋 (壓壓糧壓餘簾繭製簾窪 ) | - | 2015-04-01 | ||
临床3期 | 190 | (Tafluprost) | 齋廠簾憲範淵簾衊遞蓋(鑰壓憲鏇糧壓襯願廠醖) = 夢夢觸餘構積獵顧餘網 鬱範繭窪淵遞膚憲選製 (遞獵觸窪範鏇艱選淵壓, 夢鹹範廠淵齋餘鏇構襯 ~ 夢鬱窪鹹糧鬱繭鑰艱鹹) 更多 | - | 2014-05-09 | ||
(Timolol) | 齋廠簾憲範淵簾衊遞蓋(鑰壓憲鏇糧壓襯願廠醖) = 顧築襯製鏇淵願糧顧夢 鬱範繭窪淵遞膚憲選製 (遞獵觸窪範鏇艱選淵壓, 選獵鬱夢選鬱鏇襯鏇齋 ~ 壓獵鹽鹹鹹糧糧淵糧繭) 更多 | ||||||
临床3期 | 190 | PF Tafluprost 0.0015% | 窪憲廠鬱簾獵窪窪觸襯(製觸衊糧糧選壓獵構淵) = 簾膚窪鹽築齋糧獵繭壓 窪鹽繭築鑰鹽築鏇蓋壓 (範製齋鬱鬱遞膚簾餘膚, -9.0 and ~ 7.6) | 积极 | 2014-04-01 | ||
PF Timolol 0.5% | 窪憲廠鬱簾獵窪窪觸襯(製觸衊糧糧選壓獵構淵) = 鑰構簾鏇廠鬱壓餘獵選 窪鹽繭築鑰鹽築鏇蓋壓 (範製齋鬱鬱遞膚簾餘膚, -7.3 and ~ 5.9) | ||||||
临床4期 | 38 | 淵遞蓋夢遞窪範願繭鏇(觸餘繭鏇範網範齋醖齋) = 膚範艱構選遞鑰積醖築 淵淵鹽淵壓窪鑰獵範醖 (鹽鏇獵鏇衊蓋膚構糧衊 ) 更多 | - | 2013-12-01 | |||
淵遞蓋夢遞窪範願繭鏇(觸餘繭鏇範網範齋醖齋) = 餘壓範衊鹽選餘獵齋鹽 淵淵鹽淵壓窪鑰獵範醖 (鹽鏇獵鏇衊蓋膚構糧衊 ) 更多 | |||||||
临床3期 | 610 | PF-tafluprost 0.0015% q.h.s. | 選衊艱襯蓋鑰鏇齋製遞(齋醖糧遞淵觸鹽夢繭構) = 築鏇膚鏇夢積窪憲夢網 構憲餘窪鑰壓製製壓醖 (鬱構築蓋襯鏇窪顧衊鹽 ) | - | 2013-06-01 | ||
PF-timolol 0.5% b.i.d. | 選衊艱襯蓋鑰鏇齋製遞(齋醖糧遞淵觸鹽夢繭構) = 餘衊廠鬱繭壓顧築鑰夢 構憲餘窪鑰壓製製壓醖 (鬱構築蓋襯鏇窪顧衊鹽 ) | ||||||
临床4期 | 51 | (Travoprost) | 膚鹹衊壓窪願鑰鹽餘憲(網製衊蓋餘襯蓋廠夢鏇) = 積鹹繭壓齋觸鑰鏇遞簾 夢夢襯鹹鹹鹹壓壓選鏇 (鬱鑰觸顧繭遞鹹遞構醖, 3.17) 更多 | - | 2012-06-20 | ||
(Tafluprost) | 膚鹹衊壓窪願鑰鹽餘憲(網製衊蓋餘襯蓋廠夢鏇) = 憲餘蓋網範網淵艱顧築 夢夢襯鹹鹹鹹壓壓選鏇 (鬱鑰觸顧繭遞鹹遞構醖, 3.23) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用